ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Aug 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
October 2026
Nuclear Technology
September 2026
Fusion Science and Technology
August 2026
Latest News
LLNL, Ampera partner to develop thorium-based TRISO fuel
Lawrence Livermore National Laboratory has formed a strategic partnership with Ampera to develop the company’s nuclear fuel concept through a project named THUNDER, for Thorium Unimodal Droplet Ejection for Reactors.
The focus of THUNDER is fabricating TRISO made with kernels of thorium rather than the usual uranium. LLNL and Ampera will evaluate and optimize liquid metal–jetting technology to produce highly uniform, spherical kernels of thorium-232 for later processing into TRISO fuel.
V. Abella, R. Miró, B. Juste, G. Verdú
Nuclear Technology | Volume 175 | Number 1 | July 2011 | Pages 53-57
Technical Paper | Special Issue on the 16th Biennial Topical Meeting of the Radiation Protection and Shielding Division / Radiation Transport and Protection | doi.org/10.13182/NT11-A12269
Articles are hosted by Taylor and Francis Online.
This work is focused on coupling PLanUNC (PLUNC), a set of software tools for radiotherapy treatment planning (RTP), with MCNP5 Monte Carlo N-Particle transport code, utilizing the RANDO phantom as the patient model and the Elekta Precise linac as the irradiation source for comparison. Thus, the main goal of this paper is to compare the results obtained from the default calculations of the treatment plan software with those obtained via the implementation of MCNP5 calculations. Monte Carlo techniques have been proved to be a more accurate dose calculation aid than conventional treatment planning systems, having the only limitation of computer time. The implementation of MCNP5 calculations in a commercial RTP software aims to provide more accurate dose mapping of the patient in reasonable computer times. The results obtained in this paper represent a significant contribution in the development of RTP patient dose simulations.